A European Medicines Company committee now recommends withdrawing advertising authorization for Tavneos, an Amgen drug marketed in Europe by a CSL Restricted subsidiary. In the meantime, an FDA proposal to withdraw the drug from the U.S. market is ready to go to a listening to.
The publish EMA: Amgen, Vifor Inflammatory Drug’s Advantages No Longer Outweigh Dangers appeared first on MedCity Information.
